Abstract: Dry eye disease (DED) is a multifactorial and prevalent disease associated with ocular surface inflammation and impaired lubrication. In recent years, numerous studies have demonstrated that perioperative pharmacological use, surgical trauma, individual factors, and postoperative inflammatory responses are associated with postoperative DED. Cyclosporine selectively regulates T cells, protecting goblet cells and conjunctival epithelial cells while promoting tear secretion. As a result, it effectively alleviates dry eye symptoms in patients, improving the precision of surgeries and patient satisfaction. Currently, cyclosporine is widely used in the clinical treatment of perioperative dry eye, achieving favorable outcomes.  (Int Rev Ophthalmol, 2024, 48: 103-108)

Key words: cyclosporine, dry eye disease, perioperative period